Will the development of pharmaceutical industry be delisted?

No, as of May 30, 2023, there was no news of Kaituo Pharmaceutical's delisting. Founded in 2009, Capital Pharmaceutical Co., Ltd. focuses on the development and industrialization of potential "first-class" and "first-class" innovative drugs, and strives to become a leading enterprise in the research, development and commercialization of innovative therapies. On May 22nd, 2020, Capital Pharmaceutical was officially listed on the main board of The Stock Exchange of Hong Kong Limited. After years of development, the company focused on androgen receptor (AR) and tumor-related diseases, and developed a multi-channel product portfolio. These products cover high-incidence cancers and other diseases that do not meet the clinical needs all over the world, including COVID-19, prostate cancer, breast cancer, liver cancer, alopecia and acne. To explore the pharmaceutical industry, diversified product lines including small molecule innovative drugs, biological innovative drugs and combination therapy are expected to be laid out, including seven new drug projects under clinical research-two androgen receptor (AR) antagonists, ALK- 1 monoclonal antibodies, mTOR kinase targeting inhibitors, hedgehog /SMO inhibitors, AR-PROTAC compounds and PD-L/kloc-0. The company has more than 1 10 patents in the world, and many projects are listed as major new drug creation projects in the 12th Five-Year Plan and the 13th Five-Year Plan.